Early screening for prostate cancer could become as easy for men as personal pregnancy testing is for women, thanks to UC Irvine research published today in the Journal of the American Chemical Society.
[More]
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
[More]
Men ages 55 to 69 who are considering prostate cancer screening should talk with their doctors about the benefits and harms of testing and proceed based on their personal values and preferences, according to a new clinical practice guideline released today by the American Urological Association.
[More]
US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy.
[More]
US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy.
[More]
With the help of genetics, prostate specific antigen screenings may become more accurate and reduce the number of unnecessary prostate biopsies, according to a new study from Northwestern Medicine.
[More]
Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with non-obese men, and were at a greater risk for subsequently developing prostate cancer, according to researchers at Columbia University's Mailman School of Public Health.
[More]
A new analysis has found that the loss or amplification of particular DNA regions contributes to the development of prostate cancer, and that patients with two of these DNA changes have a high likelihood of dying from the disease.
[More]
A team led by Massachusetts General Hospital researchers has identified a genetic signature that appears to reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer.
[More]
Genetic variants have been identified which can increase serum prostate specific antigen concentrations and prostate cancer risk. A new study published in The Journal of Urology reports that correcting PSA levels for these genetic variants can have significant consequences, including avoiding unnecessary biopsies for some men and eliminating false complacency for others.
[More]
Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease.
[More]
A study at the Virginia-Maryland Regional College of Veterinary Medicine has identified a chicken-killing virus as a promising treatment for prostate cancer in humans.
[More]
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 175 national research and training grants totaling $79,073,250 for fiscal year 2013.
[More]
Do the results of recent randomized trials justify the recent U.S. recommendation against yearly measurement of prostate-specific antigen (PSA) as a screening test for prostate cancer? That's the topic of debate in a special "point/counterpoint" section in the April issue of Medical Care.
[More]
New evidence from Sweden confirms previous studies which suggest that functional outcomes after radical prostatectomy may vary between surgeons, especially in relation to continence.
[More]
The digital rectal exam is an important screening test that can discover prostate cancer that a prostate-specific antigen or PSA test may not, despite the higher sensitivity of the PSA test, according to Penn State College of Medicine researchers.
[More]
A genetic score based on PCa risk-associated single nucleotide polymorphisms is an independent predictor of prostate biopsy outcomes, suggest the results of a new study conducted by a group from the Department of Urology Huashan Hospital, Fudan University in Shanghai, China.
[More]
New research from The Cancer Institute of New Jersey suggests that more stringent criteria may be needed for African American men with prostate cancer when considering active surveillance of the disease.
[More]
Determining the androgen content in prostate tissue could predict patients’ responses to androgen deprivation therapy and the risk for castration-resistant prostate cancer, show study findings.
[More]
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option.
[More]